



RxGen, Inc. and Dr. Keith Ward Begin Publishing African Green Monkey Validation Work

Hamden, CT February 1st, 2008 --- As part of its ongoing preclinical model validation initiative, RxGen announces that the company has begun to publish on the pharmacokinetic behavior of compounds in the African green monkey. The work, to be published in conjunction with Dr. Keith Ward later this month in *Drug Metabolism and Disposition*, utilizes approved drugs that have published pharmacokinetic parameters in rodent, dog, non-human primate and human. This subset of drugs was taken from chemically different classes of compounds and from different therapeutic areas in order to provide a relevant cross-section of reference compounds.

The study successfully demonstrated that the African green monkey represents a viable model for determining the pharmacokinetic parameters of therapeutics dosed intravenously and can act as a basis for the extrapolation to human pharmacokinetic parameters. RxGen plans to expand upon this initial work by widening the scope of the validation to include: oral dosing, competitive dosing, *in vitro* protein binding, *in vitro* metabolism (including metabolic ID), *in vitro* inhibition and *in vitro* induction.

About RxGen

RxGen, Inc. is a privately held biotechnology and preclinical research organization based in New Haven, CT, providing primate models related to the central nervous system, metabolism, and ophthalmic related disorders to the pharmaceutical and biotechnology industries. In addition to providing specialty contract research services, RxGen leverages its unique resources and capabilities to validate novel therapeutic products and technologies on a partnership basis. For more information about RxGen, please visit www.rx-gen.com.

For further information, please contact:
Christopher Stanley, Chief Business Officer
Direct: (512) 897-7020
E-mail: cstanley@rx-gen.com